Volta

Diagnostic Performance of a Combined Rapid Antigen Test for Detecting SARS‐CoV‐2, Influenza Virus, and Respiratory Syncytial Virus in Symptomatic Patients in Tertiary Care

Unknown authors · 2025
hash_id: 01e5a4ffc5aca674e8521e78a3d7253db8552e3625b53062aa2e0c69a5b7426a · DOI: 10.1002/jmv.70493

Rapid antigen diagnostic tests (RDTs) can rapidly detect respiratory pathogens, allowing for the prompt initiation of infection control measures and the prevention of nosocomial spread within hospital settings. In this study, we prospectively evaluated the diagnostic performance of a combined RDT from AllTest Biotech for the simultaneous detection of SARS-CoV-2, influenza virus (IV-A/B), and respiratory syncytial virus (RSV). We compared its diagnostic performance to the Xpert-Xpress-SARS-CoV-2/Flu/RSV molecular test using 100 naso-oropharyngeal swabs (Ct-values ≤ 35), collected from symptomatic patients with acute respiratory tract infections (RTIs) at our tertiary care hospital. The RDT showed a sensitivity of 60% (95%CI: 43.4%-74.7%) for SARS-CoV-2, with lower sensitivities for RSV at 60.0% (95%CI: 38.9%-78.2%) and IV-A/B at 54.3% (95%CI: 36.9%-70.8%). Higher sensitivities of 100% …

Reference & gravity metrics

Citations
0
Citations / yr
0.00
RCR
Mass
0.00
Depth
0.00
Momentum
0.000
Burn rate
0.00 ATP/day
Start price
25.00 ATP

Secondary-market trade history

No secondary-market trades recorded for this Volta yet.

References (0)

No outbound references recorded.

Cited by (1)

Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection secondary